[MP-202525] Cosibelimab (cutaneous squamous cell carcinoma)
Last updated 18.06.2026
Project no.:
MP-202525
Report type:
Joint Clinical Assessment, JCA
Status:
Commission work started
Department/Division:
Drug Assessment
Topic:
Cancer
Indication:
Tretament of cutaneous squamous cell carcinoma
Note:
his Joint Clinical Assessment (JCA) is being conducted in cooperation with the Haute Autorité de santé (HAS) France.
Further background information can be found here: European health technology assessment
| Stage | Date |
|---|---|
| Start | 2nd quarter, 2026 |
| voraussichtlicher Abschluss | 2nd quarter, 2026 |